Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

scientific article

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JNCI/DJX014
P932PMC publication ID5409000
P698PubMed publication ID28376152

P50authorIsabella SperdutiQ37383620
Henrik J. DitzelQ41135530
Mariano ProvencioQ53051637
Antonio PassaroQ60687407
Sara PilottoQ62554605
Trever G BivonaQ90929253
Carles Codony-ServatQ91318922
P2093author name stringJie Yang
Santiago Viteri
Noemi Reguart
Mariacarmela Santarpia
Niki Karachaliou
Rafael Rosell
Caicun Zhou
Jia Wei
Peng Cao
Xuefei Li
Sonia Rodriguez
Alain Vergnenegre
Alberto Verlicchi
Chunping Hu
Xueting Cai
Patrick C Ma
Enric Carcereny
Chiara Lazzari
Andres Felipe Cardona
Jose Luis Ramirez
Jose Miguel Sanchez
Imane Chaib
Ana Drozdowskyj
Cristina Queralt
Itziar de Aguirre
Carles Codony Servat
Charo Garcia Campelo
Christina Teixido
Filipo de Marinis
Guillermo Lopez Vivanco
Kirstine Jacobson
Migual Angel Molina
Raimon Puig de la Bellacasa
Roger Estrada
P2860cites workβ-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesisQ24306274
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasQ24669579
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialQ27851712
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerQ28259999
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathwaysQ28274882
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6Q28637521
Drug combination studies and their synergy quantification using the Chou-Talalay methodQ29617422
Screening for epidermal growth factor receptor mutations in lung cancerQ29619696
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agentsQ30502341
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.Q33861952
A gp130-Src-YAP module links inflammation to epithelial regenerationQ34465259
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 functionQ35895556
Signaling networks assembled by oncogenic EGFR and c-MetQ36392991
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesQ37058831
Roles of unphosphorylated STATs in signalingQ37118445
Genetics and biomarkers in personalisation of lung cancer treatmentQ38131166
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.Q38971290
TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.Q39036426
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.Q39571776
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutationsQ39712642
Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokinQ45021806
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.Q54620289
P433issue9
P407language of work or nameEnglishQ1860
P577publication date2017-09-01
P1433published inJournal of the National Cancer InstituteQ400279
P1476titleCo-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
P478volume109

Reverse relations

cites work (P2860)
Q54939484A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Q41471047Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
Q90572093Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
Q48183995Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
Q59798144Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Q43991475Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Q50056486Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis
Q58093858Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Q43651454Dual roles of yes-associated protein (YAP) in colorectal cancer
Q55314894Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
Q91798036Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Q83225269Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
Q90555965ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer
Q92424714Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy
Q93351826Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
Q49501422Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Q64116828Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer
Q49340076Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
Q64054076Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway
Q97538337Mechanisms of resistance to osimertinib
Q65000281Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway.
Q61799008Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer
Q92593655Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma
Q38598893Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Q64238500Prognostic significance of nuclear Yes-associated protein 1 in patients with nonsmall cell lung cancer: A systematic review and meta-analysis
Q45822425Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).
Q52317592STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.
Q52317261TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.
Q47828321TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3.
Q60908274The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer
Q47100314The combination of checkpoint immunotherapy and targeted therapy in cancer
Q90713517The prognostic value of YAP1 on clinical outcomes in human cancers
Q92809901Tumor mutation burden and recurrent tumors in hereditary lung cancer
Q50112440Tumour heterogeneity and resistance to cancer therapies
Q46915997Understanding and targeting resistance mechanisms in NSCLC.
Q58607426Unique MicroRNA and mRNA Interactions in -Mutated Lung Adenocarcinoma
Q49569691YAP regulates PD-L1 expression in human NSCLC cells

Search more.